226 related articles for article (PubMed ID: 9426205)
1. Protein tyrosine kinases and cancer.
Kolibaba KS; Druker BJ
Biochim Biophys Acta; 1997 Dec; 1333(3):F217-48. PubMed ID: 9426205
[No Abstract] [Full Text] [Related]
2. Signal transduction by wild-type and leukemogenic Abl proteins.
Raitano AB; Whang YE; Sawyers CL
Biochim Biophys Acta; 1997 Dec; 1333(3):F201-16. PubMed ID: 9426204
[No Abstract] [Full Text] [Related]
3. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation.
Ludwig L; Kessler H; Wagner M; Hoang-Vu C; Dralle H; Adler G; Böhm BO; Schmid RM
Cancer Res; 2001 Jun; 61(11):4526-35. PubMed ID: 11389085
[TBL] [Abstract][Full Text] [Related]
4. Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation.
Murakami H; Iwashita T; Asai N; Shimono Y; Iwata Y; Kawai K; Takahashi M
Biochem Biophys Res Commun; 1999 Aug; 262(1):68-75. PubMed ID: 10448070
[TBL] [Abstract][Full Text] [Related]
5. [Tyrosine kinase: implications in tumor pathology and therapeutic perspectives].
Peyrade F; Taillan B; Lebrun C; Baron V; Dujardin P
Rev Med Interne; 1998 May; 19(5):366-72. PubMed ID: 9775178
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms involving an expanding erbB/EGF receptor family of tyrosine kinases in human neoplasia.
Di Fiore PP; Kraus MH
Cancer Treat Res; 1992; 61():139-60. PubMed ID: 1360229
[No Abstract] [Full Text] [Related]
7. A chimeric EGFR/neu receptor in studies of neu function.
Lehtola L; Lehväslaiho H; Koskinen P; Alitalo K
Cancer Treat Res; 1992; 61():213-28. PubMed ID: 1360234
[No Abstract] [Full Text] [Related]
8. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
Okuda K; Golub TR; Gilliland DG; Griffin JD
Oncogene; 1996 Sep; 13(6):1147-52. PubMed ID: 8808688
[TBL] [Abstract][Full Text] [Related]
9. Ret receptor tyrosine kinase activates extracellular signal-regulated kinase 2 in SK-N-MC cells.
van Weering DH; Medema JP; van Puijenbroek A; Burgering BM; Baas PD; Bos JL
Oncogene; 1995 Dec; 11(11):2207-14. PubMed ID: 8570170
[TBL] [Abstract][Full Text] [Related]
10. A mutation in the RET proto-oncogene in Hirschsprung's disease affects the tyrosine kinase activity associated with multiple endocrine neoplasia type 2A and 2B.
Cosma MP; Panariello L; Quadro L; Dathan NA; Fattoruso O; Colantuoni V
Biochem J; 1996 Mar; 314 ( Pt 2)(Pt 2):397-400. PubMed ID: 8670046
[TBL] [Abstract][Full Text] [Related]
11. The role of Ets transcription factors in the development and function of the mammalian immune system.
Bassuk AG; Leiden JM
Adv Immunol; 1997; 64():65-104. PubMed ID: 9100980
[No Abstract] [Full Text] [Related]
12. Identification of SNT/FRS2 docking site on RET receptor tyrosine kinase and its role for signal transduction.
Kurokawa K; Iwashita T; Murakami H; Hayashi H; Kawai K; Takahashi M
Oncogene; 2001 Apr; 20(16):1929-38. PubMed ID: 11360177
[TBL] [Abstract][Full Text] [Related]
13. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.
Plaza Menacho I; Koster R; van der Sloot AM; Quax WJ; Osinga J; van der Sluis T; Hollema H; Burzynski GM; Gimm O; Buys CH; Eggen BJ; Hofstra RM
Cancer Res; 2005 Mar; 65(5):1729-37. PubMed ID: 15753368
[TBL] [Abstract][Full Text] [Related]
14. [Role of the ETS transcription factors in the control of endothelial-specific gene expression and in angiogenesis].
Lelièvre E; Lionneton F; Soncin F
Bull Cancer; 2001 Feb; 88(2):137-42. PubMed ID: 11257588
[TBL] [Abstract][Full Text] [Related]
15. [The GDNF family: from neurotrophic factors to oncogenesis].
Poteriaev DA; Saarma M
Mol Biol (Mosk); 2001; 35(2):309-20. PubMed ID: 11357413
[TBL] [Abstract][Full Text] [Related]
16. Receptor tyrosine kinase signaling in vascular development.
Merenmies J; Parada LF; Henkemeyer M
Cell Growth Differ; 1997 Jan; 8(1):3-10. PubMed ID: 8993829
[No Abstract] [Full Text] [Related]
17. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
[TBL] [Abstract][Full Text] [Related]
18. Multiple GPI-anchored receptors control GDNF-dependent and independent activation of the c-Ret receptor tyrosine kinase.
Trupp M; Raynoschek C; Belluardo N; Ibáñez CF
Mol Cell Neurosci; 1998 May; 11(1-2):47-63. PubMed ID: 9608533
[TBL] [Abstract][Full Text] [Related]
19. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation.
Iwashita T; Asai N; Murakami H; Matsuyama M; Takahashi M
Oncogene; 1996 Feb; 12(3):481-7. PubMed ID: 8637703
[TBL] [Abstract][Full Text] [Related]
20. Signaling in leukemia: which messenger to kill?
Pear WS
J Clin Invest; 2000 Feb; 105(4):419-22. PubMed ID: 10683370
[No Abstract] [Full Text] [Related]
[Next] [New Search]
